Key result
Cervicothoracic transcutaneous electrical nerve stimulation reduced the washout rate of cardiac sympathetic activity compared with sham in heart failure patients.
Why the study?
Cardiac sympathetic overdrive impairs contractile function and predicts mortality in HF, prompting evaluation of cervicothoracic transcutaneous electrical nerve stimulation as a nonpharmacological therapy.
Does cervicothoracic transcutaneous electrical nerve stimulation (CTENS) reduce cardiac sympathetic overdrive in patients with heart failure?
RCT (n=17)
Double-blind
crossover
Does cervicothoracic transcutaneous electrical nerve stimulation (CTENS) reduce cardiac sympathetic overdrive in patients with heart failure?
Short-term cervicothoracic transcutaneous electrical nerve stimulation (CTENS) attenuates cardiac sympathetic overdrive in heart failure patients, particularly those with preserved autonomic innervation, offering a potential nonpharmacological neuromodulatory therapy.
Answers are grounded in this paper and cite their sources.
CTENS attenuates sympathetic overdrive in HF; extends neuromodulation options but leaves clinical outcome benefits open.
Cardiac sympathetic overdrive provides inotropic support to the failing heart. However, as myocardial insult evolves, this compensatory response impairs contractile function and constitutes an independent mortality predictor and a primary target in the treatment of heart failure (HF). In this prospective, randomized, double-blind, controlled crossover trial, we proposed cervicothoracic transcutaneous electrical nerve stimulation (CTENS) as a nonpharmacological therapy on cardiac sympathetic activity in patients with HF. Seventeen patients with HF were randomly assigned to an in-home CTENS (30 min twice daily, 80-Hz frequency, and 150-μs pulse duration) or a control intervention (Sham) for 14 consecutive days. Following a 60-day washout phase, patients were crossed over to the opposite intervention. The heart-to-mediastinum ratio (HMR) and washout rate (WR) (indexes of sympathetic innervation density and activity from planar 123iodo-metaiodobenzylguanidine myocardial scintigraphy images, respectively), as well as blood pressure (BP) and heart rate (HR), were quantified before and after each intervention. HMR, BP, and HR did not change throughout the study. Nonetheless, CTENS reduced WR (CTENS −4 ± 10 vs. Sham +5 ± 15%, P = 0.03) when compared with Sham. When allocated in two independent groups, preserved (PCSI, HMR > 1.6, n = 10) and impaired cardiac sympathetic innervation (ICSI, HRM ≤1.6, n = 7), PCSI patients showed an important attenuation of WR (−11 ± 9 vs. Sham +8 ± 19%, P = 0.007) after CTENS. Nonetheless, neither Sham nor CTENS evoked changes in WR of the ICSI patients ( P > 0.05). These findings indicate that CTENS attenuates the cardiac sympathetic overdrive in patients with HF and a preserved innervation constitutes an essential factor for this beneficial neuromodulatory impact. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Identifier: NCT03354689. NEW & NOTEWORTHY We found that short-term cervicothoracic transcutaneous electrical nerve stimulation (CTENS) attenuates cardiac sympathetic overdrive in patients with heart failure and a preserved autonomic innervation may constitute an essential factor to maximize this beneficial neuromodulatory effect. CTENS then emerges as an alternative noninvasive and nonpharmacological strategy to attenuate exaggerated cardiac sympathetic drive in patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Campos et al. (2019) conducted an RCT in heart failure (n=17). cervicothoracic transcutaneous electrical nerve stimulation (CTENS) vs. Sham was evaluated on washout rate (WR) (p=0.03). Cervicothoracic transcutaneous electrical nerve stimulation reduced the washout rate of cardiac sympathetic activity compared with sham in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: